Cellestis (CST)

Want access to our research?

Overview

Current recommendation

Members Only

12 month range

Members Only

Business risk

Members Only

Share price risk

Members Only

Maximum portfolio weighting

Members Only

Cellestis markets the QuantiFERON-TB Gold diagnostic test for tuberculosis, which is now regarded as clearly superior to the traditional skin test. The company has approval to sell the blood-test based product in the US, Canada, Europe, Australia, Japan and Taiwan.

InvestSMART Publishing Pty Ltd holds Australian Financial Securities Licence (AFSL) 282288.
The content of this website is general in nature and does not take the personal situation of any user of this website into consideration.
A user of this website should seek financial advice specific to that user’s situation before making any financial decision.
Past performance of any security or financial product is not a reliable indicator of future performance. InvestSMART Publishing Pty Ltd
encourages users of this website to view investing as a long-term pursuit.